(S)-(−)-carbidopa
Carbidopa, sold under the brand name Lodosyn, is a medication used primarily in the treatment of Parkinson's disease. It is a DOPA decarboxylase inhibitor — that is, it blocks the enzyme aromatic L-amino acid decarboxylase (DDC) in the peripheral nervous system, preventing the premature conversion of levodopa to dopamine outside the brain. Because carbidopa cannot cross the blood-brain barrier, it has no effect on DDC activity within the central nervous system, allowing a greater proportion of co-administered levodopa to reach the brain intact.
Key facts
- Drug.elimination_half life
- 2 hours
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 460017946
- Drug.IUPAC_name
- (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
- Drug.image
- Carbidopa.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Carbidopa ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Lodosyn
- Drug.licence_EU
- yes
- Drug.licence_US
- Carbidopa
Article
8 sectionsContents
- Medical uses
- Parkinson's disease
- Serotonergic Enhancement
- Pharmacology
- Chemistry
- Synthesis
- References
- External links
Carbidopa, sold under the brand name Lodosyn, is a medication used primarily in the treatment of Parkinson's disease. It is a DOPA decarboxylase inhibitor — that is, it blocks the enzyme aromatic L-amino acid decarboxylase (DDC) in the peripheral nervous system, preventing the premature conversion of levodopa to dopamine outside the brain. Because carbidopa cannot cross the blood-brain barrier, it has no effect on DDC activity within the central nervous system, allowing a greater proportion of co-administered levodopa to reach the brain intact.
== Medical uses ==
Gallery (2)
Connections
Categories
Antiparkinsonian agentsAromatic L-amino acid decarboxylase inhibitorsCatecholaminesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs missing an ATC codeECHA InfoCard ID from WikidataPeripherally selective drugsPhenethylhydrazines